Atlas Venture Life Science Advisors’s Replimune Group REPL Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,098,300	Closed	-$18.9M	–	15
2024 Q2	$18.9M	Hold	2,098,300	–	–	1.99%	10
2024 Q1	$17.1M	Hold	2,098,300	–	–	1.58%	11
2023 Q4	$17.7M	Hold	2,098,300	–	–	2.11%	9
2023 Q3	$35.9M	Hold	2,098,300	–	–	5.56%	6
2023 Q2	$48.7M	Hold	2,098,300	–	–	6.06%	7
2023 Q1	$37.1M	Hold	2,098,300	–	–	5.02%	8
2022 Q4	$57.1M	Sell	2,098,300 -1,010,000	-32%	-$21M	6.87%	7
2022 Q3	$53.7M	Sell	3,108,300 -101,327	-3%	-$1.93M	5.92%	5
2022 Q2	$56.1M	Hold	3,209,627	–	–	9.38%	4
2022 Q1	$54.5M	Hold	3,209,627	–	–	6.89%	6
2021 Q4	$87M	Buy	+3,209,627	New	+$96M	7.99%	4

Other funds holding REPL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atlas Venture Life Science Advisors's REPL Position: Q3 2024 in Review

Atlas Venture Life Science Advisors sold out of Replimune Group (REPL) in Q3 2024, closing a stake of 2,098,300 shares — an estimated $18.9M sold.

Atlas Venture Life Science Advisors first reported a position in REPL in Q4 2021 and held it in 11 quarters. The position peaked at $87M in Q4 2021. 144 funds tracked by Wall St. Rank hold REPL as of Q3 2024.

Atlas Venture Life Science Advisors reported no remaining Replimune Group position as of Q3 2024 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 2,098,300 Replimune Group shares in Q3 2024, an estimated $18.9M.
Atlas Venture Life Science Advisors first reported a position in Replimune Group in Q4 2021 and held it in 11 quarters.
Atlas Venture Life Science Advisors's Replimune Group position peaked at $87M in Q4 2021.
144 funds tracked by Wall St. Rank held Replimune Group as of Q3 2024.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.